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A dissolution test for mianserin hydrochloride in coated tablets containing 30 mg was developed and validated using a fast ultraviolet 
spectrophotometric method. The appropriate conditions were determinate after testing sink conditions, agitation speed and 
dissolution medium. The sink conditions tested showed that mianserin hydrochloride was soluble in 0.01 and 0.1 M hydrochloric 
acid (HCl), acetate buffer pH 4.1 and 5.0 and phosphate buffer pH 6.8. Then, dissolution tests were performed to investigate the 
drug release in each medium. Optimal conditions to carry out the dissolution test were 900 mL 0.1 M HCl and USP apparatus 2 
(paddle) at 50 rpm stirring speed. The quantification method was also adapted and validated. The UV method showed specificity, 
linearity, precision and accuracy. The in vitro dissolution test can be used to evaluate the drug release profile and the data was used 
as an aid to establish a possible correlation with in vivo data. 
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Introduction  
 
Mianserin hydrochloride (Fig. 1) is a drug for the treatment 
of depressive illness and depression associated with anxiety. 
It is classified as an atypical antidepressant, based on their 
mechanism of action is not defined. Acts by blocking 
presynaptic alpha-2 receptors in the brain, resulting in higher 
levels of norepinephrine in the synaptic cleft and has 
antagonist activity at serotonin receptors [1,2]. 
In the literature is not described the biopharmaceutics 
classification of mianserin hydrochloride, but we believe that 
the drug is a class III based on data of solubility and 
bioavailability. In the case of high solubility/low permeability 
drugs (class III), permeability is the rate controlling step and 
a limited IVIVC may be possible, depending on the relative 
rates of dissolution and intestinal transit. IVIVC is defined as 
the correlation between in vitro dissolution and in vivo input 
rate and may be used as an alternative to minimize 
unnecessary tests with humans [3]. The biopharmaceutics 
classification system (BCS) suggests that for high solubility, 
high permeability (class I) drugs and in some instances for 
high solubility, low permeability (class III) drugs, 85% 
dissolution in 0.1 M HCl in 15 minutes can ensure that the 
bioavailability of the drug is not limited by dissolution. In 
these cases, the rate limiting step for drug absorption is gastric 
emptying [3].  
There is real need to develop dissolutions tests that can 
predict more effectively the in vivo behavior of dosage forms, 
should lead not only to reduce costs and work needed the 
development of a pharmaceutical form, but also the number 
and size of clinical studies required and more reliable quality 
control. 
Dissolution testing should be carried out using basket at 
50/100 or paddle at 50/75, at 15 min intervals to generate a 
profile. To evaluate the profile of drugs that dissolve quickly, 
sampling should occur at shorter intervals, from 5 to 10 min 
[3].  
Drug absorption from a solid dosage form after oral 
administration depends on the release of the drug substance 
from the product, the dissolution or solubilization of the drug 
under physiological conditions and the permeability across 
the gastrointestinal tract. Then, in vitro dissolution may be 
relevant to the prediction of in vivo performance [3]. A more 
discriminating dissolution method is preferred because the 
test will indicate possible changes in the quality of the product 
before in vivo performance is affected [4]. 
Although the literature describe some analytical methods for 
quantification of mianserin hydrochloride in biological fluids 
[2,5,6] and pharmaceutical formulation [7], there is no 
dissolution test for this pharmaceutical dosage form reported. 
The aim of the present study was to develop dissolution test 
and validate an analytical method in order to evaluate the 
release profile of this drug.  
 
                 
Figure 1. Chemical structure of mianserin hydrochloride. 
  
Material and methods 
 
Instrumentation 
 
The dissolution tests were performed in a Vankel® VK 7010 
multi-bath (n=8), auto-sampling consisting of a bidirectional 
peristaltic pump, VK 750D digitally controlled heater, in 
accordance with United States Pharmacopoeia (USP) general 
methods [8]. Spectral and absorbance measurements were 
performed with an UV-Vis Shimadzu model UV 160A using 
quartz cells and detection at 278 nm. The Digimed 
potenciometer, model DM-20 (São Paulo, Brazil) was used to 
determine the pH of the solutions. The HPLC system (Agilent 
1200 series, Santa Clara, USA) consisted of a G1311A 
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quaternary pump, G1322A vacuum degasser, G1316A 
thermostat column compartment, G1329A standard auto 
sampler and G1315B diode array detector set at 278 nm. 
Chromatographic analysis were performed in an Ace RP-18 
octadecyl silane column (250mm×4.6mm i.d., particle size 5 
µm) maintained at ambient temperature (25 ºC). The mobile 
phase was composed of methanol, monobasic potassium 
phosphate buffer and triethylamine solution adjusted to pH 
7.0 in isocratic mode at a flow rate of 1.0 mL/min and the 
sample injection volume was 20 µL. 
 
Material and Reagents 
 
Mianserin hydrochloride reference standard (99.90%) was 
kindly supplied by Pharmaceutical Industry Organon 
(Schering-Plough, São Paulo, Brazil) and the commercial 
tablets Tolvon® was obtained in the local market. The 
excipients of  pharmaceutical formulation were starch, silicon 
dioxide, magnesium stearate, methylcellulose, calcium 
dibasic phosphate, hypromellose, macrogol and titanium 
dioxide. Water was purified using Millipore® system. All the 
other reagents were of analytical grade and buffer solutions 
were prepared according to USP 42 [8]. 
 
Dissolution tests conditions 
 
The dissolution profiles should be performed in at least three 
different dissolution media, within the physiological pH 
range [3]. The selection of the dissolution medium is made by 
considering, in part, the solubility of the drug in order to 
ensure sink conditions [9]. The sink conditions were 
determined in different solvents: 0.01 and 0.1 M HCl, acetate 
buffer pH 4.1 and 5.0 and phosphate buffer pH 6.8. Water is 
not tested, since it is not an ideal dissolution medium. First, 
because the variability of the quality of the water from 
different sources, and second, the variability of the pH from 
day to day [3, 8]. For dissolution tests, 900 mL of each 
medium were deaerated, by stirring and heating, and 
maintained at 37 ± 0.5 ºC. USP apparatus, paddle and basket, 
were tested. For paddle was tested stirring speeds of 50 and 
75 rpm and for basket was tested 75 and 100 rpm. The test 
time was set on 90 min. 
 
Validation 
 
In order to demonstrate whether the method was adequate for 
dissolution test purposes, it was validated through the 
analysis of specificity, linearity, precision and accuracy 
[3,8,9]. 
 
Stability 
 
Stability of mianserin hydrochloride in the dissolution 
medium selected was evaluated using standard and sample 
solutions. The solutions were kept at room temperature        
(25 ºC) for 24 h. Aliquots of the solutions were analyzed at 
time 0, 1 and 24h. The obtained results were compared with 
a freshly solution. 
 
 
 
Specificity 
 
It is necessary to demonstrate that the results are not affected 
by placebo constituents [8]. Placebo sample of commercial 
product (Tolvon®) was prepared in its usual compositions. 
The equivalent of an average weight of the mixture of 
excipients was transferred to separate vessels (n = 2) with  
900 mL of the dissolution medium at 37 ± 0.5 ºC and stirred 
for  1 h at 150 rpm using paddle (USP apparatus 2). After 1 
h, aliquots of these solutions were filtered and analyzed by 
the UV method at 278 nm. Placebo interference is available 
by the formula: 100C(AP/AS)(V/L), in which C is the 
concentration (mg/mL) of standard solution; AP and AS are 
the absorbances of placebo and standard; V is the volume of 
the medium and L is the label claim (mg). According to USP, 
the interference should not exceed 2.0%. 
 
Linearity 
 
Linearity is established by preparing solutions, ranging in 
concentration from below the lowest expected concentration 
to above the highest concentration during release. Aliquots of 
a 100.0 μg/mL solution of mianserin hydrochloride reference 
standard, prepared in 0.1 M HCl, were transferred to 20 mL 
volumetric flasks to obtain the final concentration of 5.0, 
10.0, 15.0, 20.0, 25.0, 30.0 and 40.0 μg/mL. To evaluate the 
linearity of the analytical method, three standard curves were 
constructed in three different days. The linearity was 
evaluated by linear regression analysis, which was calculated 
by the least squares regression method and analysis of 
variance (ANOVA). 
 
Precision 
 
Repeatability and intermediate precision were used to assess 
the precision of the method. Repeatability was evaluated 
through relative standard deviation (RSD) from the recovery 
data at 100% level [4] at two different days and the 
intermediate precision through the RSD inter-day. The 
recovery data were performed, in triplicate, by adding an 
amount of powder equivalent to 30.0 mg (100% of the 
nominal assay) of mianserin hydrochloride reference standard 
to a placebo sample. The dissolution test was done for 30 min 
using 900 mL of dissolution medium 0.1 M HCl at 37 ±        
0.5 ºC, apparatus 2 (paddle) rotating at 50 rpm. Aliquots of       
10.0 mL were filtered with 0.45 µm nylon filter and analyzed 
by UV method at 278 nm. 
 
Accuracy 
 
This parameter was determined by the recovery test, which 
consists in adding known amounts of mianserin 
hydrochloride reference standard to placebo solution at 10, 
100 and 150% (3.0, 30.0 and 45.0 mg) of the nominal assay 
of mianserin. These concentrations were determine based on 
other papers published in the literature. The dissolution test 
was done for 30 min using 900 mL of dissolution medium 0.1 
M HCl at 37 ± 0.5 ºC, USP apparatus 2 rotating at 50 rpm. 
Aliquots of 10.0 mL were filtered with 0.45 µm nylon filter 
and analyzed by UV method at 278 nm. Each concentration 
was prepared in duplicate. 
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Robustness 
 
It was evaluated by the influence of dissolution medium 
deaeration affects the liberation profile of mianserin 
hydrochloride from the tablets. Medium deaeration was used 
to eliminate air bubbles before the dissolution test. 
 
Dissolution profiles 
 
The dissolution profiles were obtained after the determination 
of the best dissolution conditions tests. Aliquots of 10.0 mL 
were withdrawn from each vessel without replacement of 
dissolution medium. Later, calculations were performed for 
volume correction. The times selected were: 5; 10; 15; 30; 45; 
60 and 90 min. The samples were first filtered in a 10.0 µm 
filter and then in 0.45 µm nylon filter. The samples were 
analyzed by UV method at 278 nm. 
 
In vitro-in vivo correlation 
 
The data was used as an aid to establish a possible correlation 
with in vivo data. The average plasma concentration versus 
time curve was fitted with a non-linear software (Micromath 
Scientist®, v.2.01) using a one-compartment model. An 
IVIVC for mianserin hydrochloride was evaluated by plotting 
the mean percentage of drug absorbed (FA) versus the mean 
percentage of drug dissolved (FD). 
 
Results and discussion 
 
The sink conditions tested showed that mianserin 
hydrochloride was soluble in 0.01 and 0.1 M HCl, acetate 
buffer pH 4.1 and 5.0 and phosphate buffer pH 6.8. Then, 
dissolution tests were performed to investigate the drug 
release in each medium. Initially was used a validated 
stability-indicating HPLC method [10] to analyze the 
dissolution profile of the samples (Fig. 2). 
 
Figure 2. Dissolution profiles of mianserin hydrochloride tablets 
using acetate buffer pH 4.1, acetate buffer pH 5.0 and phosphate 
buffer pH 6.8 and apparatus 2 rotating at 75 rpm. 
 
However, optimal conditions to carry out the dissolution test 
were 900 mL 0.1 M HCl at 37 ± 0.5 ºC, USP apparatus 2 
(paddle) at 50 rpm stirring speed using UV method at 278 nm 
(Fig. 3). The UV method requires no expensive or complex 
equipment and needs no toxic solvents [11]. The preferred 
method of analysis is spectrophotometric determination 
because results can be obtained faster, the analysis is simpler 
and fewer solvents are used, making this valuable in routine 
analysis [4,12]. The choice of 0.1 M HCl as medium is due to 
its good solubility, accessibility, low cost and the fact that is 
a typical dissolution medium [9]. 
To evaluate mianserin hydrochloride stability, the standard 
and sample solutions dissolved in 0.1 M HCl, were kept at 
room temperature for a period of 24 h. According to the 
literature, the acceptable range for solution stability is 98-
102% of the initial value [9]. The solutions remained stable 
for the time period specified. 
 
 
Figure 3. Tablets dissolution profile using HCl 0.1 M and paddle at 
50 rpm. 
  
The specificity analysis of placebo solution revealed that the 
UV method suffered no interference from the formulation 
excipients when the solution is filtered by        0.45 µm nylon 
filter. However, when the placebo solution was only filtered 
by 10.0 µm filter, the interference from pharmaceutical 
excipients is above the allowed (Fig. 4). According to the 
calculation of specificity recommended by USP, the 
interference of excipients was less than 2.0%. Thus, the UV 
method is useful to quantify mianserin hydrochloride in 
pharmaceutical formulation from the dissolution tests. 
 
 
Figure 4. UV spectrum of mianserin hydrochloride reference 
standard (__) and placebo (….) before (A) and after (B) filtration 
with 0.45 µm nylon filter to the dissolution test in 0.1 M HCl at 37± 
0.5 ºC and paddle rotating at 150 rpm for 1h. 
  
To assess the linearity, three standard curves for mianserin 
hydrochloride were constructed, plotting concentrations 
(μg/mL) versus absorbance and showed good linearity on the 
5.0 – 40.0 μg/mL range. The representative linear equation 
was y= 0.0073x + 0.0111 and the correlation coefficient was 
r = 0.9998. The data were validated by means of the analysis 
of variance (ANOVA), which demonstrated significant linear 
regression and no significant linearity deviation (p<0.05) 
(Fcal = 1.15). 
The precision of the dissolution tests was determined by 
repeatability (intra-day) and intermediate precision (inter- 
day) and it was expressed as RSD (%). The low values of 
relative standard deviations for the repeatability (1.32% 
and1.05%) and intermediate precision (1.77%) demonstrated 
adequate precision of the analytical method (Table 1). 
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Table 1. Precision of the dissolution method for mianserin. 
Samples Assay (%)   
  Day 1 Day 2 
1 102.73 99.40 
2 104.77 101.80 
3 101.47 99.78 
Mean 102.99 100.33 
RSD (%) 1.32 1.05 
Mean/RSD Interday:   101.66 / 1.77% 
 
The accuracy was demonstrated by the recovery of known 
amounts of mianserin hydrochloride in the dissolution 
vessels. Percentage recoveries from 95.0% to 105.0% are 
recommended [4,8]. In the accuracy test, three concentrations 
were evaluated (3.33, 33.33 and 50.0 μg/mL) and mean 
recoveries were 99.08 ± 1.95, 102.17 ± 1.88 and 100.27 ± 
0.81%, respectively. 
In the evaluation of the robustness of the method [13], the 
presence of possible air bubbles in the dissolution medium no 
interference in the dissolution profile of the mianserin 
hydrochloride in tablets.  
To establish a possible correlation with in vivo data, was used 
the pharmacokinetic data available from the literature [2]. In 
this paper referenced, the values of Cmax (peak plasma 
concentration) and tmax (time to reach Cmax) were 
calculated and the others parameters were calculated using 
one compartmental model by Drug and Statistics Software. 
Based on these results, the plasma concentration versus time 
profile curve was transformed into percentage of drug 
absorbed (FA) versus time, using Wagner-Nelson method 
(Fig. 5). 
 
 
Figure 5. Percentage of drug absorbed (FA) versus time curve for 
mianserin hydrochloride tablets using Wagner-Nelson method. 
 
The level-A correlation is the highest level of correlation that 
can be obtained. Represents a point to point relationship 
between in vitro dissolution data and in vivo absorption data 
of the drug from the dosage form [14].  
The analysis of percentage of drug absorbed (FA) versus the 
percentage of drug dissolved (FD) cannot be evaluated by 
linear regression, because there was not obtained a straight 
(fig. 6). It was not possible to establish a level-A in vitro-in 
vivo correlation for mianserin hydrochloride and one factor 
that may have hindered the correlation was the rapid drug 
release in the initial points of dissolution test. For BCS class 
III drugs - high solubility, low permeability - there is a limited 
crossing of the GI wall. In vitro dissolution will not predict in 
vivo absorption. It was not expect a level A correlation, but a 
limited correlation was possible. 
 
 
Figure 6. Plot of mean percentage of drug absorbed (FA) versus 
mean percentage of drug dissolved (FD) for Tolvon®. 
  
Conclusions  
 
The dissolution test developed and validated for mianserin 
hydrochloride was considered satisfactory. The method has 
the advantages of being very easy, fast and simple. The better 
conditions for dissolution was: 900 mL of medium containing  
0.1 M HCl, USP apparatus 2 (paddle) at 50 rpm and 37 ±      
0.5 ºC. The UV method showed specificity, linearity, 
precision and accuracy. The in vitro dissolution test can be 
used to evaluate the drug release profile, but it was not 
possible to establish a correlation with in vivo data. 
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